
Amneal Pharmaceuticals (NYSE:AMRX) brought in sales totaling $536.90 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 235.83%, resulting in a loss of $20.46 million. Amneal Pharmaceuticals collected $528.59 million in revenue during Q3, but reported earnings showed a $6.09 million loss.